These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

363 related articles for article (PubMed ID: 34448189)

  • 1. [Practical aspects of the application of CAR T cells and management of their toxicities].
    Bücklein V; Blumenberg V; Subklewe M
    Dtsch Med Wochenschr; 2021 Sep; 146(17):1129-1137. PubMed ID: 34448189
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanisms and Management of Chimeric Antigen Receptor T-Cell Therapy-Related Toxicities.
    Dholaria BR; Bachmeier CA; Locke F
    BioDrugs; 2019 Feb; 33(1):45-60. PubMed ID: 30560413
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Managing the toxicities of CAR T-cell therapy.
    Neelapu SS
    Hematol Oncol; 2019 Jun; 37 Suppl 1():48-52. PubMed ID: 31187535
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Axicabtagene ciloleucel and brexucabtagene autoleucel in relapsed and refractory diffuse large B-cell and mantle cell lymphomas.
    Reagan PM; Friedberg JW
    Future Oncol; 2021 Apr; 17(11):1269-1283. PubMed ID: 33448873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Riding the storm: managing cytokine-related toxicities in CAR-T cell therapy.
    Hughes AD; Teachey DT; Diorio C
    Semin Immunopathol; 2024 Jul; 46(3-4):5. PubMed ID: 39012374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Assessment and management of cytokine release syndrome and neurotoxicity following CD19 CAR-T cell therapy.
    Chou CK; Turtle CJ
    Expert Opin Biol Ther; 2020 Jun; 20(6):653-664. PubMed ID: 32067497
    [No Abstract]   [Full Text] [Related]  

  • 7. Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies.
    Freyer CW; Porter DL
    J Allergy Clin Immunol; 2020 Nov; 146(5):940-948. PubMed ID: 32771558
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Concise Review of Neurologic Complications Associated with Chimeric Antigen Receptor T-cell Immunotherapy.
    Ruff MW; Siegler EL; Kenderian SS
    Neurol Clin; 2020 Nov; 38(4):953-963. PubMed ID: 33040871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current understanding and management of CAR T cell-associated toxicities.
    Brudno JN; Kochenderfer JN
    Nat Rev Clin Oncol; 2024 Jul; 21(7):501-521. PubMed ID: 38769449
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Insights into cytokine release syndrome and neurotoxicity after CD19-specific CAR-T cell therapy.
    Gauthier J; Turtle CJ
    Curr Res Transl Med; 2018 May; 66(2):50-52. PubMed ID: 29625831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety profile of chimeric antigen receptor T-cell immunotherapies (CAR-T) in clinical practice.
    Bonaldo G; Montanaro N; AlbertoVaccheri ; Motola D
    Eur J Clin Pharmacol; 2021 Aug; 77(8):1225-1234. PubMed ID: 33608749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neurotoxicity and Cytokine Release Syndrome After Chimeric Antigen Receptor T Cell Therapy: Insights Into Mechanisms and Novel Therapies.
    Siegler EL; Kenderian SS
    Front Immunol; 2020; 11():1973. PubMed ID: 32983132
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety evaluation of axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma.
    Nath K; Wudhikarn K; Alarcon Tomas A; Perales MA
    Expert Opin Drug Saf; 2023 Jan; 22(1):5-15. PubMed ID: 36737060
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chimeric Antigen Receptor T-Cell Therapies for Aggressive B-Cell Lymphomas: Current and Future State of the Art.
    Abramson JS; Lunning M; Palomba ML
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():446-453. PubMed ID: 31099671
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Medium-term follow-up of patients treated with chimeric antigen receptor T cells (CAR T cells): Recommendations of the Francophone Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC)].
    Alsuliman T; Drieu La Rochelle L; Campidelli A; Duléry R; Fayard A; Mamez AC; Mear JB; Schneider PO; Trevet A; Vicente C; Yakoub-Agha I
    Bull Cancer; 2021 Dec; 108(12S):S65-S71. PubMed ID: 33678408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management.
    Brudno JN; Kochenderfer JN
    Blood Rev; 2019 Mar; 34():45-55. PubMed ID: 30528964
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed/refractory large B-cell lymphoma.
    Rejeski K; Perez A; Sesques P; Hoster E; Berger C; Jentzsch L; Mougiakakos D; Frölich L; Ackermann J; Bücklein V; Blumenberg V; Schmidt C; Jallades L; Fehse B; Faul C; Karschnia P; Weigert O; Dreyling M; Locke FL; von Bergwelt-Baildon M; Mackensen A; Bethge W; Ayuk F; Bachy E; Salles G; Jain MD; Subklewe M
    Blood; 2021 Dec; 138(24):2499-2513. PubMed ID: 34166502
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Primer on Chimeric Antigen Receptor T-cell Therapy-related Toxicities for the Intensivist.
    Ong SY; Baird JH
    J Intensive Care Med; 2024 Oct; 39(10):929-938. PubMed ID: 37899577
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cellular therapy: Immune-related complications.
    Oved JH; Barrett DM; Teachey DT
    Immunol Rev; 2019 Jul; 290(1):114-126. PubMed ID: 31355491
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reactions Related to CAR-T Cell Therapy.
    Miao L; Zhang Z; Ren Z; Li Y
    Front Immunol; 2021; 12():663201. PubMed ID: 33995389
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.